| Year |
Citation |
Score |
| 2018 |
Saha SK. Abstract A072: Effect of pharmacologic inhibition of mutant IDH in cholangiocarcinoma Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A072 |
0.305 |
|
| 2016 |
Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, et al. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery. 6: 727-39. PMID 27231123 DOI: 10.1158/2159-8290.Cd-15-1442 |
0.324 |
|
| 2016 |
Kugel S, Sebastián C, Fitamant J, Ross KN, Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, Ramaswamy S, Sadreyev RI, Goren A, Deshpande V, Bardeesy N, et al. Abstract PR09: Loss of SIRT6 reactivates the RNA-binding protein lin28b to drive pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-Pr09 |
0.323 |
|
| 2015 |
Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, et al. Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. PMID 26580013 DOI: 10.1038/Nature16136 |
0.321 |
|
| 2014 |
Saha SK, Parachoniak CA, Bardeesy N. IDH mutations in liver cell plasticity and biliary cancer. Cell Cycle (Georgetown, Tex.). 13: 3176-82. PMID 25485496 DOI: 10.4161/15384101.2014.965054 |
0.305 |
|
| 2014 |
Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes & Development. 28: 479-90. PMID 24589777 DOI: 10.1101/Gad.231233.113 |
0.318 |
|
| 2008 |
Oganesyan G, Saha SK, Pietras EM, Guo B, Miyahira AK, Zarnegar B, Cheng G. IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody production. The Journal of Biological Chemistry. 283: 802-8. PMID 17925397 DOI: 10.1074/Jbc.M704755200 |
0.729 |
|
| 2007 |
He JQ, Oganesyan G, Saha SK, Zarnegar B, Cheng G. TRAF3 and its biological function. Advances in Experimental Medicine and Biology. 597: 48-59. PMID 17633016 DOI: 10.1007/978-0-387-70630-6_4 |
0.787 |
|
| 2007 |
He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. The Journal of Biological Chemistry. 282: 3688-94. PMID 17158868 DOI: 10.1074/Jbc.M610271200 |
0.761 |
|
| 2006 |
He JQ, Zarnegar B, Oganesyan G, Saha SK, Yamazaki S, Doyle SE, Dempsey PW, Cheng G. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. The Journal of Experimental Medicine. 203: 2413-8. PMID 17015635 DOI: 10.1084/Jem.20061166 |
0.763 |
|
| 2006 |
Pietras EM, Saha SK, Cheng G. The interferon response to bacterial and viral infections. Journal of Endotoxin Research. 12: 246-50. PMID 16953977 DOI: 10.1177/09680519060120040601 |
0.776 |
|
| 2006 |
Saha SK, Pietras EM, He JQ, Kang JR, Liu SY, Oganesyan G, Shahangian A, Zarnegar B, Shiba TL, Wang Y, Cheng G. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. The Embo Journal. 25: 3257-63. PMID 16858409 DOI: 10.1038/Sj.Emboj.7601220 |
0.703 |
|
| 2006 |
Saha SK, Cheng G. TRAF3: a new regulator of type I interferons. Cell Cycle (Georgetown, Tex.). 5: 804-7. PMID 16582590 DOI: 10.4161/Cc.5.8.2637 |
0.634 |
|
| 2006 |
Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, Perry A, Cheng G. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature. 439: 208-11. PMID 16306936 DOI: 10.1038/Nature04374 |
0.759 |
|
| 2005 |
O'Connell RM, Vaidya SA, Perry AK, Saha SK, Dempsey PW, Cheng G. Immune activation of type I IFNs by Listeria monocytogenes occurs independently of TLR4, TLR2, and receptor interacting protein 2 but involves TNFR-associated NF kappa B kinase-binding kinase 1. Journal of Immunology (Baltimore, Md. : 1950). 174: 1602-7. PMID 15661922 DOI: 10.4049/Jimmunol.174.3.1602 |
0.802 |
|
| 2005 |
O'Connell R, Saha S, Cheng G. Combating Bacterial Pathogens Through Host Defense Gene Programs Current Immunology Reviews. 1: 43-54. DOI: 10.2174/1573395052952950 |
0.606 |
|
| 2004 |
O'Connell RM, Saha SK, Vaidya SA, Bruhn KW, Miranda GA, Zarnegar B, Perry AK, Nguyen BO, Lane TF, Taniguchi T, Miller JF, Cheng G. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. The Journal of Experimental Medicine. 200: 437-45. PMID 15302901 DOI: 10.1084/Jem.20040712 |
0.751 |
|
| Show low-probability matches. |